<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01414894</url>
  </required_header>
  <id_info>
    <org_study_id>37222-A</org_study_id>
    <nct_id>NCT01414894</nct_id>
  </id_info>
  <brief_title>Intensive Management of Pressure and Volume Expansion in Patients With Subarachnoid Hemorrhage</brief_title>
  <acronym>IMPROVES</acronym>
  <official_title>Intensive Management of Pressure and Volume Expansion in Patients With Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of our study is to determine how well Triple-H works and how safe it is. The&#xD;
      investigators are hoping to determine the effects of starting the therapy early and to&#xD;
      explore if hypervolemia and/or hypertension are beneficial, and what the optimal target&#xD;
      ranges are.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy of Triple-H therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Our primary endpoint is to determine the feasibility of the pilot study within the ICU setting and collect preliminary estimates for sample size calculations.</measure>
    <time_frame>6 months</time_frame>
    <description>1. Estimation of the eligible population once specific study inclusion &amp; exclusion criteria are applied 2. Estimation of enrollment projections, retention, attrition &amp; losses to follow up; 3. Assessment of compliance with protocol instructions; 4. Evaluation of protocol violations; 5. Achievement of pre-determined hemodynamic goals in each study group.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Normal Fluids &amp; Normal Blood Pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Increased Fluids &amp; Normal Blood Pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Fluids &amp; Higher Blood Pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Increased Fluids &amp; Higher Blood Pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluid manipulation</intervention_name>
    <description>Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.</description>
    <arm_group_label>Increased Fluids &amp; Higher Blood Pressure</arm_group_label>
    <arm_group_label>Increased Fluids &amp; Normal Blood Pressure</arm_group_label>
    <arm_group_label>Normal Fluids &amp; Higher Blood Pressure</arm_group_label>
    <arm_group_label>Normal Fluids &amp; Normal Blood Pressure</arm_group_label>
    <other_name>Hypervolemia</other_name>
    <other_name>Normovolemia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Pressure Manipulation</intervention_name>
    <description>Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.</description>
    <arm_group_label>Increased Fluids &amp; Higher Blood Pressure</arm_group_label>
    <arm_group_label>Increased Fluids &amp; Normal Blood Pressure</arm_group_label>
    <arm_group_label>Normal Fluids &amp; Higher Blood Pressure</arm_group_label>
    <arm_group_label>Normal Fluids &amp; Normal Blood Pressure</arm_group_label>
    <other_name>Conventional Blood Pressure</other_name>
    <other_name>Augmented Blood Pressure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age more than or equal to 18 years&#xD;
&#xD;
          2. Aneurysmal SAH of any clinical grade&#xD;
&#xD;
          3. Head computed tomography demonstrating SAH&#xD;
&#xD;
          4. Cerebral angiography revealing the presence of cerebral aneurysm(s) in a location that&#xD;
             explains the SAH&#xD;
&#xD;
          5. Treatment of aneurysm with clipping or coiling must be carried out prior to&#xD;
             randomization and within 72 hours of bleeding&#xD;
&#xD;
          6. Signed consent by study participant or applicable legal representative within 72 hours&#xD;
             after SAH&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of traumatic SAH&#xD;
&#xD;
          2. Non-aneurysmal SAH as indicated by no demonstrable aneurysm by cerebral angiography&#xD;
&#xD;
          3. Presence of an unsecured intracranial aneurysm(s) at risk of rupture that in the&#xD;
             opinion of the Investigator would compromise the safety of the patient or the quality&#xD;
             of the data&#xD;
&#xD;
          4. Delayed referral with clipping/coiling greater than 72 hours after the initial&#xD;
             bleeding&#xD;
&#xD;
          5. Time of symptom onset cannot be reliably determined&#xD;
&#xD;
          6. Intracranial hypertension (ICP &gt;25 mm Hg) at the time of screening&#xD;
&#xD;
          7. History within the past six months and/or physical findings on admission of&#xD;
             decompensated congestive heart failure (NYHA functional class III or IV, or objective&#xD;
             class C or D)&#xD;
&#xD;
          8. Acute, evolving or recent myocardial infarction&#xD;
&#xD;
          9. Cardiac arrhythmia or second and third degree atrio-ventricular block causing&#xD;
             hemodynamic instability&#xD;
&#xD;
         10. Chronic renal failure requiring dialysis&#xD;
&#xD;
         11. Suspected or confirmed pregnancy&#xD;
&#xD;
         12. Non English speaking&#xD;
&#xD;
         13. A condition that would preclude the performance of the neurobehavioral test battery&#xD;
             due to a prior diagnosis of Alzheimer's disease, stroke, degenerative condition,&#xD;
             cerebral tumor, or mental retardation&#xD;
&#xD;
         14. Severe terminal disease with life expectancy less than 6 months&#xD;
&#xD;
         15. Refusal of consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miriam Treggiari, MD, PhH, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2011</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Miriam Treggiari</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

